{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:23:28Z","timestamp":1790796208271,"version":"4.1.0"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T00:00:00Z","timestamp":1536796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100009705","name":"Council for Chemical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009705","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["currentprotocols.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CP Cytometry"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The use of targeted therapy is growing in the setting of hematopoietic neoplasms. Flow cytometry is a cornerstone of residual disease monitoring post therapy in this group of malignancies. Often, there is overlap between antigens targeted by immunotherapies and gating reagents utilized for population identification by flow cytometry. Such overlap can render a previously excellent gating reagent inadequate for disease detection. Recently, several anti\u2013CD19 T cell\u2013engaging immunotherapeutic agents and an anti\u2010CD22 immunotoxin have been FDA approved for use in B lymphoblastic leukemia (B\u2010LL), with an anti\u2013CD22 T cell\u2013engaging agent in development. In the setting of such targeted therapies, CD19 and CD22 expression may be altered, compromising the use of these reagents for identification of abnormal blasts. We describe herein a strategy for flow cytometric monitoring for residual disease in patients with B\u2010LL post T cell\u2013engaging anti\u2010CD19 and anti\u2010CD22 therapies. \u00a9 2018 by John Wiley &amp; Sons, Inc.<\/jats:p>","DOI":"10.1002\/cpcy.44","type":"journal-article","created":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T18:27:09Z","timestamp":1536863229000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Flow Cytometric Monitoring for Residual Disease in B Lymphoblastic Leukemia Post T Cell Engaging Targeted Therapies"],"prefix":"10.1002","volume":"86","author":[{"given":"Sindhu","family":"Cherian","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, University of Washington  Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryalice","family":"Stetler\u2010Stevenson","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, CCR, NIH  Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,9,13]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22130"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.15218"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2016.09.006"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21482"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441"},{"key":"e_1_2_5_7_1","first-page":"1","article-title":"CAR T cell therapy for multiple myeloma: Where are we now and where are we headed","author":"Ghosh A.","year":"2017","journal-title":"Leukemia & Lymphoma"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2016.10.004"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2016.1161185"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-438002"},{"key":"e_1_2_5_12_1","article-title":"A QA program for MRD testing demonstrates that systematic education can reduce discordance among experienced interpreters","author":"Keeney M.","year":"2017","journal-title":"Cytometry:. Part B, Clinical Cytometry"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0568-6"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000000436"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-580068"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.156"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20469"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402989"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25410"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620715588916"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21108"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21239"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/0471142956.cy0621s33"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0405-4"}],"container-title":["Current Protocols in Cytometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpcy.44","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/currentprotocols.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpcy.44","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T12:08:57Z","timestamp":1694866137000},"score":1,"resource":{"primary":{"URL":"https:\/\/currentprotocols.onlinelibrary.wiley.com\/doi\/10.1002\/cpcy.44"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,13]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1002\/cpcy.44"],"URL":"https:\/\/doi.org\/10.1002\/cpcy.44","archive":["Portico"],"relation":{},"ISSN":["1934-9297","1934-9300"],"issn-type":[{"value":"1934-9297","type":"print"},{"value":"1934-9300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,13]]},"assertion":[{"value":"2018-09-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e44"}}